A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

Study Site 32, Rochester

Study Site 34, Baltimore

Study Site 19, Charlottesville

Study Site 54, Greensboro

Study Site 71, Raleigh

Study Site 50, Gastonia

Study Site 73, Mooresville

Study Site 55, Charlotte

Study Site 24, Charlotte

Study Site 21, Charleston

Study Site 72, Charleston

Study Site 53, Charlotte

Study Site 59, Jacksonville

Study Site 11, Winter Park

Study Site 62, Miami

Study Site 57, Miami

Study Site 33, Tampa

Study Site 68, Clearwater

Study Site 12, Largo

Study Site 56, Cincinnati

Study Site 13, Greenfield

Study Site 41, Minneapolis

Study Site 42, Edina

Study Site 37, Rochester

Study Site 27, Missoula

Study Site 39, Normal

Study Site 74, Oklahoma City

Study Site 26, Tulsa

Study Site 22, Dallas

Study Site 35, Dallas

Study Site 23, Waco

Study Site 10, Houston

Study Site 49, San Antonio

Study Site 25, Centennial

Study Site 36, Colorado Springs

Study Site 60, Meridian

Study Site 58, Salt Lake City

Study Site 15, Chandler

Study Site 16, Las Vegas

Study Site 43, Los Angeles

Study Site 20, San Diego

Study Site 52, Mission Viejo

Study Site 28, San Jose

Study Site 14, Bellingham

Study Site 48, Waterbury

Study Site 38, East Providence

Study Site 66, Niagara Falls

Study Site 65, Québec

Study Site 64, Trois-Rivières

Study Site 29, Romford

Study Site 94, Blackpool

Study Site 93, Prescot

Study Site 17, Northwood

Study Site 45, Hull

Study Site 30, Leicester

Study Site 46, London

Study Site 18, Manchester

Study Site 47, Newcastle upon Tyne

Study Site 31, North Shields

Study Site44, Oxford

Study Site 40, Belfast

Study Site 96, Barnsley

Study Site 97, Cannock

Study Site 95, Stockton-on-Tees

Study Site 92, Leeds

Study Site 91, Manchester